This presentation discuss how to treat hyperglycaemia in patients with type 2 …
This presentation discuss how to treat hyperglycaemia in patients with type 2 diabetes. The cornerstone in the treatment is weight loss and increased physical activity, but most patients need pharmacological treatment from the time of diagnosis in order to control hyperglycemia. Furthermore we’ll discuss the use of all diabetic agents in patient with type 2 diabetes and how it’s important that the anti diabetic treatment is individualized.
Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst
This presentation discuss the new antidiabetic agents. We have the incretin based …
This presentation discuss the new antidiabetic agents. We have the incretin based therapy which include two groups of drugs, DDP-4 inhibitors and GLP-1 receptor agonist. Furthermore we’ll provide an introduction to the hormones GLP-1 and GIP and their effect on insulin.
Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst
This presentation focuses on the treatment of hyperglycaemia with type 2 diabetes …
This presentation focuses on the treatment of hyperglycaemia with type 2 diabetes patients. We’ll provide an introduction to exenatide, liraglutide, GLP-1 receptor antagonist, combination therapy, DPP-4 inhibitor, pancreatic safety of incretin-based drugs, SGLT-2 inhibitor and glucose absorption.
Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst
This presentation provides an introduction to Sodium-glucose linked transporter 2 inhibitors (SGLT-2) …
This presentation provides an introduction to Sodium-glucose linked transporter 2 inhibitors (SGLT-2) and how it affects the blood glucose. Furthermore we’ll discuss how SGLT-2 inhibitors can be used for treating patients with type 2 diabetes. Three SGLT-2 inhibitors have been approved: Dapa, Empa and Canagliflozin, for clinical use in patients with type 2 diabetes.
Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.
